MedPath

Observational study to assess compliance, safety issues and treatment response to single pill once daily regimen of Tenofovir, Lamivudine, Efavirenz (TLE) in HIV infected adult patients

Not Applicable
Active, not recruiting
Conditions
Health Condition 1: null- HIV patients receiving ART
Registration Number
CTRI/2016/03/006742
Lead Sponsor
Department of Pharmacology IPGMER
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
150
Inclusion Criteria

i.All HIV infected adult patients (age >18 years) of either gender attending and registered to ART centre of SSKM hospital.

ii.HIV infected adult patients being initiated on fixed dose combination TLE regimen or those who are being shifted to fixed dose combination TLE regimen from other ART regimens (e.g. TL+N or ZL+E or ZL+N).

iii.Willing to provide written informed consent.

Exclusion Criteria

i.Patients who are on ART regimens other than TLE.

ii.Patients being shifted to TL+E only due to concomitant Anti Tubercular Drug administration

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.